Home › Trials › NCT07101237
Clinical trial Recruiting at 1 site Observational Ages 18 to 70

Combining advanced ultrasound and molecular analyses to map tumor differences in liver cancer

Official title: Integrative Multimodal Imaging and Multi-omics Profiling of HCC Heterogeneity: a Translational Exploratory Study Leveraging CEUS, Elastography, SMI, PAI, Multi-omics Analysis, and AI-driven Modeling to Advance Precision Diagnosis and Therapeutic Optimization

Run by Peking Union Medical College Hospital · NCT07101237 · Data updated 2026-11-12

This project tries combining multiple ultrasound techniques with molecular (multi-omics) tests to see if they can better characterize tumors and guide care for adults with primary liver cancer who are scheduled for surgery.

Quick facts

Study typeObservational
Ages18 Years to 70 Years
SexAll
Enrollment308 (estimated)
SponsorPeking Union Medical College Hospital
Academic / other
Locations1 site (Beijing)
StatusRecruiting
StartedAugust 1, 2024
Main results expectedDecember 31, 2029
Study endsDecember 31, 2030
Registry record updatedAugust 3, 2025
Trial IDNCT07101237 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18–70 with pathologically confirmed primary HCC or ICC who are scheduled for surgical resection or conversion therapy and whose lesion lies within 8 cm of the skin surface are ideal candidates.

Probably not a fit

Patients with lesion depth greater than 8 cm from the skin surface, active other malignancies, severe organ insufficiency, massive ascites, pregnancy, or known allergy to ultrasound contrast agents are unlikely to benefit or be eligible.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study collects multimodal ultrasound images (contrast-enhanced ultrasound, elastography, superb microvascular imaging, and photoacoustic imaging) together with multi-omics data from patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma. Imaging is performed preoperatively or before conversion therapy and linked to pathology, molecular profiles, and clinical outcomes to map intra- and inter-tumor heterogeneity. The team will analyze correlations between imaging features and genomic, transcriptomic, and metabolomic signatures to identify markers predictive of response or prognosis. The goal is to create integrated imaging–molecular signatures that could inform more precise preoperative diagnosis and treatment planning.

Why it matters

Potential benefit: If successful, this approach could allow clinicians to identify tumor differences earlier and choose more personalized treatments for liver cancer patients.

How similar studies have gone: Related multimodal imaging and radiogenomic studies have shown promising early signals linking imaging features to molecular profiles, but such integrated approaches remain largely exploratory and not yet proven to change outcomes in liver cancer.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

1. Age \>18 and ≤70 years;
2. Both sexes eligible;
3. Diagnosed with primary HCC or ICC;
4. Scheduled for surgical resection or conversion therapy;
5. Pathologically confirmed HCC/ICC via surgery or biopsy;
6. Posterior margin of the lesion ≤ 8 cm from the skin surface.

Exclusion Criteria:

1. Pregnancy, lactation, or planned pregnancy during the study period;
2. History of other malignancies;
3. Cardiac, pulmonary, cerebral, or renal insufficiency;
4. Lesion depth \>8 cm from the skin surface on ultrasound;
5. Massive ascites;
6. Poor compliance (e.g., inability to hold breath during examination);
7. Allergy to ultrasound contrast agents.

Where it's running

  • Peking Union Medical College Hospital
    Beijing, China     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Hepatocellular Carcinoma (HCC) 119Intrahepatic Cholangiocarcinoma (Icc) 19Primary Liver Cancer 9Peking Union Medical College Hospital 200
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.